About
Zymedi focuses on discovering and developing first-in-class therapeutics by targeting the noncatalytic regulatory functions of aminoacyl-tRNA synthetases (ARSs) for difficult-to-treat diseases including cancer, immune disorders, and neurological diseases.
Explore Zymedi's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.